Anti-Rheumatic Drugs - Chile | Statista Market Forecast

In Chile, the revenue in the Anti-Rheumatic Drugs market is estimated to reach US$61.52m in 2024.
It is projected that the revenue will experience an annual growth rate of 0.63% from 2024 to 2029, resulting in a market volume of US$63.48m by 2029.
When comparing the global market, United States is expected to generate the highest revenue in the Anti-Rheumatic Drugs market, with an estimated amount of US$34.70bn in 2024.
Chile's anti-rheumatic drug market is witnessing a surge in demand, driven by an aging population and an increasing prevalence of rheumatic diseases.

Definition:
The market Anti-Rheumatic Drugs includes medication for the treatment of the inflammatory disease rheumatism. Due to the high prevalence of rheumatism and the large size of the market, this section of immune diseases is treated as a separate market. Both steroidal and non-steroidal anti-rheumatics are included. Disease-modifying rheumatic drugs (DMARDs), such as tumor necrosis factor inhibitors (a type of biologic DMARD), are particularly important in terms of commerciality.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: AbbVie, Johnson & Johnson, Pfizer, Amgen, Roche

Drugs to treat rheumatism
Steroidal (corticosteroids) and non-steroidal anti-rheumatics
Disease-modifying antirheumatic drugs (DMARDs)
Tumor necrosis factor (TNF) inhibitors

Drugs to treat other autoimmune diseases (such as multiple sclerosis or psoriasis)
Analgetics for general use (such as paracetamol)
Treatment of osteoarthritis

The Anti-Rheumatic Drugs market in Chile has seen significant growth in recent years, driven by a combination of macroeconomic and demographic factors.

Customer preferences: Patients in Chile suffering from rheumatoid arthritis, osteoarthritis, and other rheumatic diseases have increasingly turned to Anti-Rheumatic Drugs as a means of managing their symptoms. This is in part due to a growing awareness of the benefits of early intervention and treatment, as well as the availability of a wider range of drugs and therapies.

Trends in the market: One of the key trends in the Anti-Rheumatic Drugs market in Chile has been the shift towards more targeted and personalized treatments. This has been driven by advances in technology and research, which have enabled doctors and healthcare providers to better understand the underlying causes of rheumatic diseases and to develop more effective treatments.Another trend in the market has been the growing importance of biosimilars. These are drugs that are similar to existing biologic drugs but are produced by different manufacturers and are typically less expensive. Biosimilars have become increasingly popular in Chile due to their lower cost and comparable efficacy to existing treatments.

Local special circumstances: Chile has a relatively high prevalence of rheumatic diseases, with an estimated 15% of the population suffering from some form of arthritis. This has created a significant market for Anti-Rheumatic Drugs, which is expected to continue to grow in the coming years.In addition, Chile has a well-developed healthcare system that provides universal coverage to its citizens. This has helped to ensure that patients have access to the latest treatments and therapies, and has contributed to the overall growth of the Anti-Rheumatic Drugs market.

Underlying macroeconomic factors: The growth of the Anti-Rheumatic Drugs market in Chile can also be attributed to a number of underlying macroeconomic factors. These include a growing middle class with increased purchasing power, a stable political environment, and a favorable regulatory environment that encourages investment in the healthcare sector.Overall, the Anti-Rheumatic Drugs market in Chile is expected to continue to grow in the coming years, driven by a combination of demographic, technological, and economic factors. As the market evolves, it is likely that we will see continued innovation in the development of new treatments and therapies, as well as a greater focus on personalized and targeted approaches to treatment.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.